These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15703362)

  • 1. A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects.
    Narang VS; Lulla A; Malhotra G; Purandare S
    J Clin Pharmacol; 2005 Mar; 45(3):265-74. PubMed ID: 15703362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-dose, randomized, open-label, two-period crossover bioequivalence study of a fixed-dose pediatric combination of lamivudine 40-mg, nevirapine 70-mg, and stavudine 10-mg tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
    Monif T; Rao Thudi N; Koundinya Tippabhotla S; Khuroo A; Marwah A; Kumar Shrivastav V; Tandon M; Raghuvanshi R; Biswal S
    Clin Ther; 2007 Dec; 29(12):2677-84. PubMed ID: 18201583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
    Monif T; Reyar S; Tiwari HK; Tippabhotla SK; Khuroo A; Thudi NR; Ahmed S; Raghuvanshi R
    Arzneimittelforschung; 2009; 59(2):104-8. PubMed ID: 19338141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nevirapine/lamivudine/stavudine as a combined-formulation tablet: bioequivalence study compared with each component administered concurrently under fasting condition.
    Monif T; Tippabhotla SK; Garg M; Singla AK; Vijan T
    Int J Clin Pharmacol Ther; 2006 Jun; 44(6):276-83. PubMed ID: 16800100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
    Hosseinipour MC; Corbett AH; Kanyama C; Mshali I; Phakati S; Rezk NL; van der Horst C; Kashuba AD
    AIDS; 2007 Jan; 21(1):59-64. PubMed ID: 17148968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence evaluation of a fixed dose combination lamivudine + stavudine tablet with concurrent administration of lamivudine tablet and stavudine capsule in healthy volunteers.
    Chachad S; Lulla A; Malhotra G; Purandare S
    Arzneimittelforschung; 2009; 59(10):537-40. PubMed ID: 19998583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products.
    Marier JF; Dimarco M; Guilbaud R; Dodard C; Morelli G; Tippabhotla SK; Singla AK; Thudi NR; Monif T
    J Clin Pharmacol; 2007 Nov; 47(11):1381-9. PubMed ID: 17962426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profiling and bioequivalence assessment of two marketed brands of nevirapine tablets in healthy Indian volunteers.
    Narang VS; Lulla A; Malhotra G; Purandare S
    Arzneimittelforschung; 2005; 55(10):598-603. PubMed ID: 16294506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
    Yuen GJ; Lou Y; Thompson NF; Otto VR; Allsup TL; Mahony WB; Hutman HW
    J Clin Pharmacol; 2001 Mar; 41(3):277-88. PubMed ID: 11269568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous determination of lamivudine, stavudine and nevirapine in human plasma by LC-MS/MS and its application to pharmacokinetic study in clinic.
    Li Z; Ding C; Ge Q; Zhou Z; Zhi X; Liu X
    Biomed Chromatogr; 2010 Sep; 24(9):926-34. PubMed ID: 20058328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of nevirapine, stavudine and lamivudine in Indian HIV-infected children receiving generic fixed dose combinations.
    Mukherjee A; Singla M; Velpandian T; Sirohiwal A; Vajpayee M; Singh R; Kabra SK; Lodha R
    Indian Pediatr; 2014 Mar; 51(3):191-7. PubMed ID: 24736906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
    Vanprapar N; Cressey TR; Chokephaibulkit K; Muresan P; Plipat N; Sirisanthana V; Prasitsuebsai W; Hongsiriwan S; Chotpitayasunondh T; Eksaengsri A; Toye M; Smith ME; McIntosh K; Capparelli E; Yogev R;
    Pediatr Infect Dis J; 2010 Oct; 29(10):940-4. PubMed ID: 20453709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India.
    Vezina HE; Henry K; Ravindran GD; Kurpad AV; Raj TD; Fox K; Weller D; Brundage RC; Cavert W; Balfour HH
    J Acquir Immune Defic Syndr; 2006 Feb; 41(2):131-6. PubMed ID: 16394842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
    Manosuthi W; Kiertiburanakul S; Chaovavanich A; Sungkanuparph S
    J Med Assoc Thai; 2007 Feb; 90(2):244-50. PubMed ID: 17375627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nevirapine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study.
    Laurito TL; Santagada V; Caliendo G; Oliveira CH; Barrientos-Astigarraga RE; De Nucci G
    J Mass Spectrom; 2002 Apr; 37(4):434-41. PubMed ID: 11948850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of lamivudine in human plasma by HPLC and its use in bioequivalence studies.
    Kano EK; dos Reis Serra CH; Koono EE; Andrade SS; Porta V
    Int J Pharm; 2005 Jun; 297(1-2):73-9. PubMed ID: 15907596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.
    Byakika-Tusiime J; Chinn LW; Oyugi JH; Obua C; Bangsberg DR; Kroetz DL
    PLoS One; 2008; 3(12):e3981. PubMed ID: 19096711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
    Laurent C; Kouanfack C; Koulla-Shiro S; Njoume M; Nkene YM; Ciaffi L; Brulet C; Peytavin G; Vergne L; Calmy A; Mpoudi-Ngolé E; Delaporte E
    AIDS; 2007 Mar; 21(6):768-71. PubMed ID: 17413701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.
    Ellis JC; L'homme RF; Ewings FM; Mulenga V; Bell F; Chileshe R; Molyneux E; Abernethy J; van Oosterhout JJ; Chintu C; Walker AS; Gibb DM; Burger DM
    Antivir Ther; 2007; 12(2):253-60. PubMed ID: 17503667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring dried blood spot sampling technique for simultaneous quantification of antiretrovirals: lamivudine, stavudine and nevirapine in a rodent pharmacokinetic study.
    Nirogi R; Kandikere V; Komarneni P; Aleti R; Padala N; Kalaikadhiban I; Bhyrapuneni G; Muddana N
    Biomed Chromatogr; 2012 Dec; 26(12):1472-81. PubMed ID: 22344535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.